Impact of Clinical Pharmacy Services Provided for Patients With Active Rheumatoid Arthritis

January 8, 2020 updated by: hager omar mohammed siddik
Enrolment of clinical pharmacy services in RA patients as a part of health care system has been investigated at many studies but not investigated in active RA patients before. This study aimed to detect drug therapy-related problems (DTRPs) in active rheumatoid arthritis (RA) patients and Investigate the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life (QoL). Methods:Prospective, randomized controlled study to be carried out at rheumatology outpatient clinic, Ain Shams University Hospitals on 50 patients with active RA for 6 months.determine if any drug therapy problems are present.Develop a plan of care that includes interventions to resolve drug therapy problems, achieve goals of therapy, and prevent drug therapy problems. questionnaires was used to measure functional status in RA patients using health assessment questionnaire (HAQ) and assess self-reported quality of life in patients with (RA) using rheumatoid arthritis quality of life questionnaire (RAQOL) and measure adherence using the 4-item Morisky Green Levine Medication Adherence Scale and Disease Activity Score-28 was used as an objective method to assess RA disease activity.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

54

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
    • Abasiya
      • Cairo, Abasiya, Egypt, 11566
        • Facuty of Pharmacu Ain Shams University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

rheumatoid arthritis patients from outpatient clinics - Ain shams university hospitals

Description

Inclusion Criteria:

  • Patients aged 18-60 years old
  • fulfillment of the American College of Rheumatology /European league against rheumatism (2010 ACR/EULAR ) diagnostic criteria for RA.
  • patients with active RA(defined by DAS28 score < 5.1)

Exclusion Criteria:

  • Patients with cognitive impairment.
  • The presence of hepatic or renal disease.
  • The presence of other rheumatic and connective tissue disorders.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
intervention
will be supplied by pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
Other: pharmaceutical care services
detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life
control
will received standard care by physician in attendance

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
disease activity score
Time Frame: 6 months
disease activity score-28 (DAS-28) for measuring disease activity in rheumatoid arthritis patients
6 months
Quality of life questionnaire
Time Frame: 6 months
Rheumatoid arthritis quality of life questionnaire (RAQOL) for measuring quality of life
6 months
Health assessment questionnaire
Time Frame: 6 months
Health assessment questionnaire (HAQ) for measuring functional status in rheumatoid arthritis patients
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

hager omar mohammed siddik

Investigators

  • Principal Investigator: hager omar m siddik, teaching assistant at faculty of pharmacy ain shams university

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 14, 2018

Primary Completion (Actual)

October 10, 2019

Study Completion (Actual)

December 18, 2019

Study Registration Dates

First Submitted

November 4, 2018

First Submitted That Met QC Criteria

November 13, 2018

First Posted (Actual)

November 16, 2018

Study Record Updates

Last Update Posted (Actual)

January 13, 2020

Last Update Submitted That Met QC Criteria

January 8, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 156

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rheumatoid Arthritis

Clinical Trials on pharmaceutical care services

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe